Combination of Olaparib and Navitoclax in Women With HGSC and TNBC
Condition(s):High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian CancerLast Updated:July 7, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian CancerLast Updated:July 7, 2023Recruiting
Condition(s):Breast CancerLast Updated:February 22, 2023Terminated
Condition(s):Ovarian CancerLast Updated:February 7, 2024Recruiting
Condition(s):Pulmonary Arterial HypertensionLast Updated:April 18, 2023Recruiting
Condition(s):HER2-negative Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast CancerLast Updated:April 18, 2023Recruiting
Condition(s):Advanced Breast CancerLast Updated:January 13, 2023Completed
Condition(s):Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell LymphomaLast Updated:December 7, 2023Not yet recruiting
Condition(s):Malignant Neoplasm of Breast; Breast CancerLast Updated:February 22, 2023Recruiting
Condition(s):Pulmonary Arterial HypertensionLast Updated:August 26, 2020Terminated
Condition(s):Prostate Cancer; Castration-resistant Prostate CancerLast Updated:October 31, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.